Shattuck Labs (NASDAQ:STTK) Stock Price Down 2.3%

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) dropped 2.3% during trading on Friday . The company traded as low as $2.11 and last traded at $2.11. Approximately 3,922 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 30,848 shares. The stock had previously closed at $2.16.

Analyst Upgrades and Downgrades

STTK has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Shattuck Labs in a research note on Friday, August 11th. Needham & Company LLC reduced their price objective on Shattuck Labs from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 11th.

Shattuck Labs Stock Down 2.3 %

The stock has a market capitalization of $89.61 million, a price-to-earnings ratio of -0.97 and a beta of 1.11. The business has a 50-day simple moving average of $2.53 and a two-hundred day simple moving average of $2.93.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new position in shares of Shattuck Labs in the first quarter valued at $37,000. Squarepoint Ops LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at $30,000. UBS Group AG raised its stake in Shattuck Labs by 62.3% during the 1st quarter. UBS Group AG now owns 10,978 shares of the company’s stock valued at $32,000 after purchasing an additional 4,214 shares during the period. Balyasny Asset Management LLC acquired a new stake in Shattuck Labs during the 3rd quarter valued at $35,000. Finally, Jane Street Group LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at $58,000. Institutional investors own 47.79% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.